In8bio, INC

IN8bio, Inc. has entered into a new Capital on DemandTM Sales Agreement with JonesTrading Institutional Services LLC for an at-the-market offering program, while simultaneously terminating a previous agreement with Cantor Fitzgerald & Co.

IN8bio announced first quarter 2026 financial results, highlighting progress in its gamma-delta T cell therapies and T cell engager platform, with encouraging glioblastoma data and upcoming R&D Day.

IN8bio announced positive full-year 2025 financial results, durable survival improvements in glioblastoma trials, and a strengthened financial position extending its cash runway into the first half of 2027.

IN8bio, Inc. announced the resignation of director Alan S. Roemer and the appointment of Jeremy Graff as Interim Chair of the Board, effective February 28, 2026.

IN8bio, Inc. announced the appointment of Chief Operating Officer Kate Rochlin as President, effective February 4, 2026.

IN8bio, Inc. announced a private placement to raise an initial $20.1 million, with an option for an additional $20.1 million contingent on a key clinical milestone and stock performance.

IN8bio, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, reporting a net loss of $5.1 million and highlighting substantial doubt about its ability to continue as a going concern.

IN8bio reports continued net losses and a dwindling cash position, raising substantial doubt about its ability to continue as a going concern, despite positive clinical data for INB-100 and INB-200.

IN8bio, a clinical-stage biopharmaceutical company, reported reduced net losses and operating expenses in Q2 2025, while advancing its gamma-delta T cell product candidates despite ongoing going concern doubts.

IN8BIO reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern, while focusing on pipeline prioritization and cost management.

IN8bio announced a pipeline prioritization and workforce reduction in September 2024, focusing on INB-100 development and suspending INB-400 trials.

IN8bio, a clinical-stage biopharmaceutical company, released its 10-Q filing for the quarter ended June 30, 2024, detailing financial results and providing updates on its clinical programs and financial position.

IN8bio, Inc. files an amendment to its annual report on Form 10-K to correct the exhibit list and include new certifications from its principal executive and financial officers.

IN8bio's 10-K filing reveals encouraging clinical trial results for INB-100 in AML patients, a pipeline prioritization strategy, and efforts to secure additional funding amidst going concern uncertainties.

IN8bio's 10-K filing outlines its capital structure, including common and preferred stock, warrants issued in a recent private placement, and various anti-takeover provisions.

Director Emily Fairbairn reported a gift of 724,637 shares of IN8bio common stock to a charitable foundation.

IN8BIO, INC. CEO William Ho receives a stock option grant for 154,500 shares, with vesting scheduled over four years.

IN8BIO, INC. reports that Director Luba Greenwood acquired 22,000 stock options with an exercise price of $1.58, vesting monthly starting June 9, 2026.

IN8BIO, Inc. reports that EVP and CSO Lawrence Lamb acquired 54,000 employee stock options with an exercise price of $1.58.

IN8BIO, Inc. reports that Director Emily Fairbairn acquired 22,000 stock options with an exercise price of $1.58, vesting over time.

IN8BIO, INC. Chief Financial Officer Patrick McCall was granted employee stock options for 56,250 shares of common stock.

IN8bio, Inc. has filed a definitive proxy statement for its 2026 Annual Meeting of Stockholders, seeking approval for director elections, auditor ratification, and a significant increase in its equity incentive plan share reserve.

IN8bio is asking stockholders to approve a reverse stock split to maintain its listing on the Nasdaq Capital Market and potentially improve stock marketability.

IN8bio, Inc. will hold its annual stockholders meeting on May 8, 2025, to elect directors, ratify the selection of an accounting firm, and vote on a potential reverse stock split.

IN8bio is asking stockholders to approve a reverse stock split to maintain its listing on the Nasdaq Capital Market and potentially improve stock marketability.

IN8bio, Inc. will hold its annual stockholders meeting on June 12, 2024, to elect directors and ratify the selection of its accounting firm.

IN8bio, Inc. is holding its 2024 Annual Meeting of Stockholders virtually on June 12, 2024, to elect directors and ratify the selection of its independent accounting firm.

Emily and Malcom Fairbairn have fallen below the 5% beneficial ownership threshold in IN8bio, Inc. following a significant charitable donation of shares.

Emily and Malcom Fairbairn, along with their CRUT, increased their beneficial ownership in IN8BIO, INC. to 7.5% through a $1 million investment in a recent private placement.

Bios Equity Partners and affiliated entities have amended their Schedule 13D filing for IN8BIO, INC., reporting a beneficial ownership of 4.0% of common stock following a warrant exchange and share sales.

A group of investment funds led by Bios Equity Partners has updated its beneficial ownership in IN8bio, Inc. through a warrant exchange agreement, consolidating existing warrants and providing a cash payment.

Laurence W. Lytton and Lytton-Kambara Foundation report a 9.99% passive beneficial ownership stake in IN8BIO, Inc., including common stock and warrants.

Franklin Resources, Inc. and its affiliates have reported a 9.4% beneficial ownership stake in IN8bio, Inc. common stock.

683 Capital Management, LLC and its affiliates have reported a 7.86% beneficial ownership stake in IN8BIO, Inc., including warrants.

Stonepine Capital Management and its affiliates have reported a 9.9% beneficial ownership stake in IN8BIO, Inc., comprising common stock and prefunded warrants.

Alyeska Investment Group, L.P. and its affiliates reported a 2.58% beneficial ownership stake in IN8BIO, INC., primarily through warrants.

Transcend Partners Opportunity Fund I LLC has filed an Amendment No. 2 to its Schedule 13G, disclosing a 2.6% beneficial ownership stake in IN8BIO, INC.